The Clinical Development of Thalidomide as an Angiogenesis Inhibitor Therapy for Prostate Cancer

Abstract

The purpose of this award is to evaluate the: 1) Safety and toxicity of neo-adjuvant thalidomide therapy prior to radical prostatectomy in patients with locally advanced prostate carcinoma (PCa), assessed by wound healing and peri-operative bleeding; 2) Efficacy of neo-adjuvant thalidomide treatment, as measured by the rate of tumor reduction I PSA decline while on thalidomide therapy; 3) Qualitative measurements of the in vivo effect of thalidomide therapy on the Endothelial and Epithelial compartment (PCa cells).

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2002
Accession Number
ADA416710

Entities

People

  • Danai Dlaiani

Organizations

  • The University of Texas MD Anderson Cancer Center

Tags

DTIC Thesaurus Topics

  • Chemistry
  • Data Storage Systems
  • Health Services
  • Medical Personnel

Fields of Study

  • Medicine

Readers

  • Aerospace Propulsion Engineering.
  • Immunology and Pathology
  • Oncology and Biomarker-Based Cancer Detection.